As shown in Figure 5b, on day 18, HH044 and MAC-3-190 treatments alone reduced tumor growth to 45.7% and 26.3% of the control, respectively, while anti-PD-1 monotherapy reduced the tumor volume to 44.0% of the control group. This evidence concerns the gene PDCD1 and neoplasm.